0000000000274971

AUTHOR

Sathyapalan T

showing 2 related works from this author

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

2015

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular deat…

Oralmedicine.medical_specialtyHeart diseasesGlycosylatedAdministration Oralheart failureType 2 diabetesDipeptidyl peptidase-4 inhibitorKaplan-Meier EstimatePlaceboSitagliptin PhosphateSitagliptin Cardiovascular Outcomeschemistry.chemical_compoundDrug TherapyDouble-Blind MethodInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentsGlycated HemoglobinHemoglobin A GlycosylatedAdministration Oral; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Drug Therapy Combination; Follow-Up Studies; Heart Diseases; Heart Failure; Hemoglobin A Glycosylated; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles; Medicine (all)business.industryMedicine (all)SemaglutideSitagliptin PhosphateHemoglobin AGeneral MedicineTriazolesta3121medicine.diseaseSurgeryHospitalizationCardiovascular diseaseschemistryDiabetes Mellitus Type 2SitagliptinPyrazinesAdministrationCombinationDrug Therapy CombinationGlycated hemoglobinbusinessType 2Alogliptinmedicine.drugFollow-Up StudiesNew England Journal of Medicine
researchProduct

Liraglutide and Renal Outcomes in Type 2 Diabetes.

2017

BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a co…

MaleSettore MED/09 - Medicina InternaAcute Kidney Injury; Aged; Albuminuria; Creatinine; Diabetes Mellitus Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kidney Failure Chronic; Liraglutide; Male; Middle AgedType 2 diabetes030204 cardiovascular system & hematologyurologic and male genital diseasesGLOMERULAR-FILTRATION-RATEKIDNEY-FUNCTIONDISEASElaw.inventionKidney Failurechemistry.chemical_compound0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawMedicineDiabetic NephropathiesHypoglycemic Agents.Settore MED/49 - Scienze Tecniche Dietetiche ApplicateChronicRISKKidneyAcute kidney injury11 Medical And Health SciencesGeneral MedicineAcute Kidney InjuryMiddle AgedIntention to Treat Analysismedicine.anatomical_structureCreatinineTRIALFemaleliraglutide randomized controlled trial type 2 diabetes renal outcomesLife Sciences & BiomedicineType 2Glomerular Filtration Ratemedicine.drugmedicine.medical_specialtyRenal function030209 endocrinology & metabolismCARDIOVASCULAR OUTCOMESFollow-Up Studie03 medical and health sciencesMedicine General & InternalDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicineDiabetes MellitusAlbuminuriaHumansHypoglycemic AgentsIntensive care medicineAgedCreatinineScience & Technologybusiness.industryLiraglutideMORTALITYLiraglutidemedicine.diseaseINTENSIVE GLUCOSE CONTROLINDIVIDUALSDiabetes Mellitus Type 2chemistryDiabetic NephropathieKidney Failure ChronicLEADER Steering Committee and InvestigatorsbusinessFollow-Up Studies
researchProduct